V. D. Dodge, E. M. Cox
Dodge & Cox Stock Fund
Dodge & Cox Stock Fund Elanco Animal Health stake
total: 130
Dodge & Cox Stock Fund ELAN trades
- Total transactions:
- 11
- New positions:
- 1
- Added:
- 7
- Reduced:
- 3
- Held since:
- 2021 Q3
- Held for:
- 19 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Dodge & Cox Stock Fund holds 45,270,700 Elanco Animal Health (ELAN) shares with a market value of roughly $1.08B accounting for 0.95% of the overall portfolio. To date, the estimated cost basis is nearly $19.78 for "buy" trades and estimated average "sell" price is $23.58. Dodge & Cox Stock Fund first purchased ELAN in 2021 Q3, initially acquiring about 2.05M shares. Since the initial investment in Elanco Animal Health (ELAN), Dodge & Cox Stock Fund has made 10 more transactions.
When did Dodge & Cox Stock Fund buy Elanco Animal Health (ELAN)?
Dodge & Cox Stock Fund first invested in Elanco Animal Health (ELAN) in 2021 Q3 at the reported quarter-end price of $31.89 per share.
What's the cost basis of Dodge & Cox Stock Fund's ELAN stake?
The estimated cost basis for Elanco Animal Health (ELAN) stake is around $19.78 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $19.78
- Weighted AVG sell price:
- $23.58
Dodge & Cox Stock Fund's historical trades in Elanco Animal Health
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.95%
|
45,270,700
|
$23.93
|
$1,083,327,851
|
-14.78% (-7,852,200)
|
-0.16%
|
|
2025 Q4
|
1.00%
|
53,122,900
|
$22.63
|
$1,202,171,227
|
-4.01% (-2,218,400)
|
-0.04%
|
|
2024 Q4
|
0.60%
|
55,341,300
|
$12.11
|
$670,183,143
|
-0.10% (-55,200)
|
-0%
|
|
2023 Q3
|
0.67%
|
55,396,500
|
$11.24
|
$622,656,660
|
+0.54% (+296,200)
|
+0%
|
|
2023 Q2
|
0.60%
|
55,100,300
|
$10.06
|
$554,309,018
|
+0.36% (+197,000)
|
+0%
|
|
2022 Q4
|
0.76%
|
54,903,300
|
$12.22
|
$670,918,326
|
+49.74% (+18,238,300)
|
+0.25%
|
|
2022 Q3
|
0.58%
|
36,665,000
|
$12.41
|
$455,012,650
|
+4.76% (+1,667,000)
|
+0.03%
|
|
2022 Q2
|
0.80%
|
34,998,000
|
$19.63
|
$687,010,740
|
+92.47% (+16,814,300)
|
+0.39%
|
|
2022 Q1
|
0.48%
|
18,183,700
|
$26.09
|
$474,412,733
|
+18.48% (+2,836,100)
|
+0.07%
|
|
2021 Q4
|
0.45%
|
15,347,600
|
$28.38
|
$435,564,888
|
+647.74% (+13,295,073)
|
+0.39%
|
|
2021 Q3
|
0.07%
|
$31.89
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.